The present invention relates to a compound having the structure of formula I or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, ester, optical isomer or prodrug thereof, a pharmaceutical composition comprising the compound having the structure of formula I, and an application of the compound, serving as a selective Bruton tyrosine kinase inhibitor, in the preparation of a medicine for preventing or treating heteroimmune diseases, autoimmune diseases, or cancers.